Investigating a treatment to prevent Alzheimer's disease using a specific antibody.
API A4 Alzheimer's Prevention Trial
This study is looking for older adults aged 65-80 who are at risk for Alzheimer's disease to see if a treatment called aducanumab can help prevent the disease by targeting certain proteins in the brain, and you'll either receive the treatment or a placebo over two years while we keep an eye on your thinking skills and safety.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Banner Health NIH-funded |
| Lab location | 1 site (Phoenix, United States) |
| Project ID | NIH-11014318 on NIH RePORTER |
What this research studies
This research focuses on the prevention of Alzheimer's disease (AD) by testing a treatment called aducanumab, which targets amyloid-beta proteins associated with AD. The trial will involve cognitively unimpaired individuals aged 65-80 who have specific biomarkers indicating a risk for AD. Participants will be randomly assigned to receive either the treatment or a placebo over a 24-month period, with ongoing monitoring of cognitive function and safety. The goal is to determine if this treatment can effectively reduce the risk of developing Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are cognitively unimpaired individuals aged 65-80 who test positive for amyloid-beta biomarkers and may carry the APOE4 allele.
Not a fit: Patients who are already diagnosed with Alzheimer's disease or those without amyloid-beta biomarkers are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new preventive therapy for Alzheimer's disease, potentially delaying or preventing its onset in at-risk individuals.
How similar studies have performed: Previous trials using similar approaches with aducanumab have shown promising results in reducing amyloid plaques and slowing cognitive decline in affected patients.
Where this research is happening
Phoenix, United States
- Banner Health — Phoenix, United States (Active)
Researchers
- Principal investigator: Reiman, Eric Michael — Banner Health
- Study coordinator: Reiman, Eric Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.